country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-185878

Copy Link Print Information

ZER1 binder-1

ZER1 binder-1 is a pyridazinone derivative and a binding agent for the E3 ubiquitin ligase ZER1, with an FP EC₅₀ value of 55.59 nM. ZER1 binder-1 is applicable to the research of cancers induced by human papillomavirus (HPV) infection.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 3132618-21-1
Formel: C₂₁H₁₈ClN₇O₂
Molecular Weight:435.87

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

ZER1 binder-1 Chemical Structure

CAS. Nr.: 3132618-21-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
Chemical Information
Protokoll (1)
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

^[1]

ZER1 (469-766)

55.59 nM (EC₅₀)

In Vitro

ZER1 binder-1 (Example 289) binds to purified human ZER1 (469-766) protein, with an FP EC₅₀ of 55.59 nM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

Chemical Information

CAS. Nr. 3132618-21-1
Molecular Weight 435.87
Formel C₂₁H₁₈ClN₇O₂
SMILES

O=C1N(N=CC=C1C2=CC([C@@H](N)C)=NO2)C3=CC(C4=CN(N=C4)C(C)C#N)=CC(Cl)=C3
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Protokoll

All Signal Pathway Related

Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.

Reinheit & Dokumentation

Handling Instructions (2659 KB)

Verweise

[1]. IENDERSON, Timothy J, et al. ZERI BINDERS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF. WO2026122416A1 11.06.2026.

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen